Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $0.77 in the prior trading day, Atyr Pharma Inc (NASDAQ: ATYR) closed at $0.78, up 1.33%. In other words, the price has increased by $1.33 from its previous closing price. On the day, 1.53 million shares were traded. ATYR stock price reached its highest trading level at $0.795 during the session, while it also had its lowest trading level at $0.7579.
Ratios:
Our goal is to gain a better understanding of ATYR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.93 and its Current Ratio is at 5.93. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.
On September 15, 2025, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight but kept the price unchanged to $1.
Leerink Partners Downgraded its Outperform to Market Perform on September 15, 2025, while the target price for the stock was maintained at $1.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 08 ’25 when SCHIMMEL PAUL bought 682,001 shares for $0.90 per share. The transaction valued at 612,437 led to the insider holds 1,095,024 shares of the business.
SCHIMMEL PAUL bought 317,999 shares of ATYR for $299,364 on Oct 09 ’25. The Director now owns 1,413,023 shares after completing the transaction at $0.94 per share. On Mar 17 ’25, another insider, Gross Jane A, who serves as the Director of the company, bought 3,750 shares for $4.00 each. As a result, the insider paid 15,000 and bolstered with 9,750 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATYR now has a Market Capitalization of 75988632 and an Enterprise Value of -2045365. For the stock, the TTM Price-to-Sale (P/S) ratio is 399.95 while its Price-to-Book (P/B) ratio in mrq is 0.95. Its current Enterprise Value per Revenue stands at -10.765 whereas that against EBITDA is 0.026.
Stock Price History:
The Beta on a monthly basis for ATYR is 0.61, which has changed by -0.74752474 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, ATYR has reached a high of $7.29, while it has fallen to a 52-week low of $0.64. The 50-Day Moving Average of the stock is -8.31%, while the 200-Day Moving Average is calculated to be -76.29%.
Shares Statistics:
The stock has traded on average 10.50M shares per day over the past 3-months and 1947120 shares per day over the last 10 days, according to various share statistics. A total of 97.99M shares are outstanding, with a floating share count of 95.56M. Insiders hold about 2.48% of the company’s shares, while institutions hold 63.39% stake in the company. Shares short for ATYR as of 1764288000 were 29801092 with a Short Ratio of 2.84, compared to 1761868800 on 31060738. Therefore, it implies a Short% of Shares Outstanding of 29801092 and a Short% of Float of 36.380002.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 8.0 analysts currently analyzing and rating the stock of Atyr Pharma Inc (ATYR).The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.12 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.77 and -$0.87 for the fiscal current year, implying an average EPS of -$0.82. EPS for the following year is -$0.56, with 10.0 analysts recommending between -$0.22 and -$0.82.
